PMID: 11929404Apr 4, 2002Paper

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

Alimentary Pharmacology & Therapeutics
Naohito ShiraiT Ishizaki

Abstract

The acid inhibitory effect of lansoprazole depends on the S-mephenytoin 4'-hydroxylase (CYP2C19) genotype status. The effect of famotidine is independent of this genotype. To investigate the acid inhibitory effects of lansoprazole vs. famotidine during the daytime and night-time with reference to different CYP2C19 genotypes. Fifteen healthy volunteers were given 20 mg famotidine twice a day or 30 mg lansoprazole once a day for 8 days. On post-dose day 8, 24-h intragastric pH monitoring was performed. During the daytime, the intragastric pH with lansoprazole was significantly higher than that with famotidine in the heterozygous extensive metabolizer group, whereas no significant difference was observed in the homozygous extensive metabolizer group. During the night-time, the intragastric pH with famotidine was quite similar to that with lansoprazole in the heterozygous extensive metabolizer and poor metabolizer groups. However, during the night-time, the intragastric pH with famotidine was significantly higher than that with lansoprazole in the homozygous extensive metabolizer group. An insufficient acid inhibition by lansoprazole during the night-time in the homozygous extensive metabolizer group could be compensated for by fam...Continue Reading

References

Apr 1, 1992·Archives of Internal Medicine·L J HixsonC D Tuohy
Dec 29, 1988·The New England Journal of Medicine·M M Wolfe, A H Soll
Nov 1, 1987·Gut·D RobertsonC L Smith
Nov 1, 1986·Digestive Diseases and Sciences·J G Moore, F Halberg
Feb 1, 1995·Digestive Diseases and Sciences·B I HirschowitzG Sachs
Dec 1, 1996·Clinical Pharmacology and Therapeutics·T KubotaT Ishizaki
May 1, 1997·Clinical Pharmacology and Therapeutics·D R SohnT Ishizaki
Jan 1, 1997·European Journal of Clinical Pharmacology·H KatsukiM Nakano
Jun 13, 1998·The American Journal of Gastroenterology·P L PeghiniD O Castell
Jan 9, 1999·Alimentary Pharmacology & Therapeutics·P O KatzD O Castell
Jan 9, 1999·Alimentary Pharmacology & Therapeutics·J G HatlebakkD O Castell
Sep 24, 1999·Alimentary Pharmacology & Therapeutics·M P Williams, R E Pounder
Sep 24, 1999·Alimentary Pharmacology & Therapeutics·T Ishizaki, Y Horai
Aug 10, 2000·Alimentary Pharmacology & Therapeutics·T KatsubeY Kinoshita
Sep 30, 2000·Alimentary Pharmacology & Therapeutics·K AdachiY Kinoshita

❮ Previous
Next ❯

Citations

Mar 5, 2009·European Journal of Clinical Pharmacology·Takahisa FurutaAkira Hishida
Mar 16, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Takahisa FurutaKyoichi Ohashi
Jun 14, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Takahisa FurutaAkira Hishida
Feb 4, 2006·Journal of Pediatric Gastroenterology and Nutrition·Marian D PfefferkornJoseph F Fitzgerald
Feb 9, 2010·Journal of Gastroenterology and Hepatology·Mitsushige SugimotoYoshio Yamaoka
Mar 16, 2004·Pharmacogenomics·Takahisa FurutaTakashi Ishizaki
Jun 1, 2012·Clinical and Experimental Gastroenterology·Mitsushige Sugimoto, Takahisa Furuta
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Larisa H CavallariAdam Bress
Dec 13, 2005·Drugs·Xavier Calvet, Fernando Gomollón
Jul 6, 2014·European Journal of Clinical Pharmacology·Mitsushige SugimotoTakahisa Furuta
Aug 17, 2006·European Journal of Clinical Pharmacology·Mateusz KurzawskiMarek Droździk
Aug 6, 2008·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Oct 19, 2010·Gastroenterology Clinics of North America·Takahisa Furuta, David Y Graham
Aug 19, 2010·British Journal of Clinical Pharmacology·Takahisa FurutaKazuo Umemura
Mar 13, 2014·Journal of Clinical Pharmacology·Takahiro UotaniTakahisa Furuta
Aug 2, 2012·Diagnostic and Therapeutic Endoscopy·Mitsushige SugimotoTakahisa Furuta
Jul 1, 2005·Drug Metabolism and Pharmacokinetics·Takahisa FurutaTakashi Ishizaki
Apr 7, 2015·Annals of the American Thoracic Society·Jason E LangUNKNOWN American Lung Association-Airways Clinical Research Centers
Jun 12, 2016·Advances in Therapy·Kazuyoshi OtakeNobuhiro Inatomi
Aug 16, 2016·Pharmacology & Therapeutics·Nobuhiro InatomiKazuyoshi Otake
Jul 13, 2004·Basic & Clinical Pharmacology & Toxicology·Ulrich KlotzGerhard Treiber
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Yiping WangZhen Guo
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Jan 31, 2019·Frontiers in Pharmacology·Mitsushige Sugimoto, Yoshio Yamaoka
May 19, 2018·World Journal of Gastrointestinal Endoscopy·Taketo OtsukaAkira Andoh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.